Market Overview

Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

Share:
Related OMER
Cantor Fitzgerald Starts Omeros With Buy, $21PT
Mid-Day Market Update: Sodastream Gains Following Earnings Beat; NewLink Genetics Shares Decline
Expect OraSure To Drop 35% (Or More) Next Week (Seeking Alpha)

In a report published Monday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ: OMER).

In the report, Wedbush noted, “A recent conversation with a high-volume cataract surgeon on OMS302's potential use enhances our outlook for Omeros. The FDA is cracking down on sterility of topical solutions used during intraocular lens replacement surgery. We recently had a conversation with a high-volume cataract surgeon about the changing regulatory landscape following sterility issues at compound pharmacies. The FDA has indicated that each patient must be given a separate bottle for topical NSAIDs and mydriatic agents. In addition, surgeons are no longer allowed to mix their own homebrews of these agents for use during surgery—a common practice.”

Omeros Corporation closed on Friday at $5.09.

Latest Ratings for OMER

DateFirmActionFromTo
Jun 2016Cantor FitzgeraldInitiates Coverage onBuy
Apr 2016Roth CapitalTerminatesBuy
Aug 2015Roth CapitalInitiates Coverage onBuy

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Liana Moussatos WedbushAnalyst Color Reiteration Analyst Ratings

 

Related Articles (OMER)

View Comments and Join the Discussion!